Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

Fineline Cube Nov 14, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...

Company Drug

Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China

Fineline Cube Nov 14, 2024

China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...

Company Deals

Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund

Fineline Cube Nov 14, 2024

Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...

Company Drug

Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment

Fineline Cube Nov 14, 2024

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC

Fineline Cube Nov 14, 2024

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...

Company Deals

Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research

Fineline Cube Nov 14, 2024

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...

Company Deals

BioNTech Seals Acquisition of China’s Biotheus for Up to $950M

Fineline Cube Nov 14, 2024

China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...

Company Deals

Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

Fineline Cube Nov 14, 2024

China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...

Company

Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value

Fineline Cube Nov 14, 2024

Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital,...

Company

FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo

Fineline Cube Nov 13, 2024

US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...

Company

AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials

Fineline Cube Nov 13, 2024

UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the...

Company

BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra

Fineline Cube Nov 13, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...

Company

Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals

Fineline Cube Nov 13, 2024

Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...

Company Deals

Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881

Fineline Cube Nov 13, 2024

China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...

Company Deals

Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange

Fineline Cube Nov 13, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...

Company Deals

Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research

Fineline Cube Nov 13, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...

Company Medical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Fineline Cube Nov 13, 2024

US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...

Company

Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra

Fineline Cube Nov 13, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...

Company

Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales

Fineline Cube Nov 13, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter...

Company Deals

Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia

Fineline Cube Nov 13, 2024

Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...

Posts pagination

1 … 306 307 308 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.